Biogen gears up Swiss manufacturing facility for potential aducanumab rollout

biogen
Biogen has delayed its regulatory filing for aducanumab until the third quarter. (Biogen)

Biogen has had a rocky road with its controversial Alzheimer's disease candidate aducanumab, which it brought back from the dead late last year. But despite postponing the drug's FDA filing by half a year, Biogen is still moving forward with plans to scale up production if aducanumab eventually passes muster.

Biogen has wrapped up construction on a "state-of-the-art" facility in Solothurn, Switzerland, that will be ready to manufacture aducanumab at scale beginning in mid-2021, CEO Michael Vounatsos told analysts on the company's first-quarter earnings call.

The Swiss facility is expected to be operational by late 2021 and will tag-team commercial aducanumab production alongside Biogen's North Carolina manufacturing facility, Vounatsos said. 

Of course, those production plans are predicated on Biogen securing an approval for aducanumab, a controversial Alzheimer's candidate co-developed with Eisai that has faced major trial disappointments and now, delays to its regulatory filings. 

RELATED: Biogen execs outline setbacks, and potential gains, from COVID-19 pandemic

Suggested Articles

Lupin Pharmaceuticals has shut down an Indian generics plant after 18 workers tested positive for COVID-19, Reuters reported.

Merck KGaA could see billions of dollars in revenue opportunity as it assists certain players with their COVID-19 scale-up, an analyst says. 

The FDA approved Johnson & Johnson's Tremfya as the first IL-23 inhibitor to treat psoriatic arthritis, joining a suite of immunology blockbusters.